Confirmation Testing Clause Samples

The Confirmation Testing clause establishes the requirement for the buyer or client to verify that goods, services, or deliverables meet specified criteria before final acceptance. Typically, this involves a defined period during which the recipient conducts tests or inspections to ensure compliance with agreed-upon standards or performance metrics. This clause ensures that any deficiencies are identified and addressed prior to final approval, thereby protecting the buyer from accepting substandard work and providing a clear process for resolving issues before completion.
POPULAR SAMPLE Copied 1 times
Confirmation Testing. (a) If an initial drug test is negative, the employer may in its sole discretion seek a confirmation test. (b) Only licensed or certified laboratories as described in subsection (9) may conduct confirmation drug tests. (c) All positive initial tests shall be confirmed using gas chromatography/mass spectrometry (GC/MS) or an equivalent or more accurate scientifically accepted method approved by the Agency for Health Care Administration or the United States Food and Drug Administration as such technology becomes available in a cost-effective form. (d) If an initial drug test of an employee or job applicant is confirmed as positive, the employer's medical review officer shall provide technical assistance to the employer and to the employee or job applicant for the purpose of interpreting the test result to determine whether the result could have been caused by prescription or nonprescription medication taken by the employee or job applicant.
View SourceView Similar (3)
Confirmation Testing. ‌ (a) For so long as an Applicant Product is an MPI Approved Product, MPI will have the right to conduct periodic confirmation tests of that MPI Approved Product to confirm that the product continues to meet the applicable MPI Standard. Upon demand by MPI, the Applicant will immediately deliver to MPI or an MPI Representative, without charge, product samples for confirmation testing pursuant to this Section. MPI attempts to minimize the need for such samples. (b) The Applicant will pay for MPI’s fees and expenses for each such confirmation test, which will be charged at the applicable fees then in effect. (c) Prior to conducting any confirmation test, MPI will notify the Applicant in writing of the name of the MPI Approved Product to be tested and the approximate test date. The Applicant will have the right to withdraw the MPI Approved Product from the MPI Approved Products List by giving notice of such withdrawal to MPI not less than 3 business days before the scheduled test date, in which event MPI will not conduct the confirmation test, the applicable product will cease to be an MPI Approved Product and the provisions of Subsection 4.7(a) and (c) will apply with respect to that product.‌ (d) On or about the test date, MPI will conduct one or more confirmation tests on that product to determine if it continues to meet the applicable MPI Standard. (e) Upon completion of the confirmation test(s) on the MPI Approved Product, MPI will provide a written report to the Applicant stating: (i) whether the product continues to be an MPI Approved Product; and (ii) if the product no longer qualifies as an MPI Applicant Product, a reasonable description of the reason(s) why the Applicant Product failed to meet the applicable MPI Standard. (f) If the product no longer qualifies as an MPI Approved Product, then the Applicant will have the right to appeal that decision, and the provisions of Section 3.4, with all necessary changes, will apply to such appeal process.
View SourceView Similar (3)
Confirmation Testing. The Contractor shall perform confirmation testing using Gas Chromatography/Mass Spectrometry (GC/MS). This testing will be conducted to the Threshold Levels designated in Section II., G., 3. Thin Layer Chromatography is not an acceptable testing method for confirmation.
View Source
Confirmation Testing. TransAct shall have the right to test and evaluate the Licensed Products for operational compatibility with TransAct systems and white label branding as and when such Licensed Products are made available for use on in BOHA! Solution. [***] will provide to TransAct all relevant documents, deliverables and other information that is reasonably necessary for TransAct to make its evaluation. If TransAct determines that such Licensed Product is deficient in one or more respects, TransAct shall notify [***] in writing outlining each deficiency, and [***] shall use its reasonable best efforts to promptly repair the deficiency. Promptly following any initial testing and evaluation, or testing and evaluation following identification of any deficiencies (and after the same have been repaired) TransAct will confirm to [***] that such Licensed Products are ready to be used in a production environment. Notwithstanding the foregoing, TransAct’s confirmation of Licensed Products shall in no way limit the performance and warranty obligations of [***] as identified in Section 1.7 and Section 8.
View Source
Confirmation Testing. Please supply a detailed description of the proposed chain of custody process that uniquely links the sample to the donor.
View Source

Related to Confirmation Testing

  • Inspection/Testing In order to assess Supplier’s work quality and/or compliance with this Order, upon reasonable notice by Buyer: (a) all goods, materials and services related to the items purchased hereunder, including, raw materials, components, assemblies, work in process, tools and end products shall be subject to inspection and testing by Buyer, its customer, representative or regulatory authorities at all places, including sites where the goods are made or located or the services are performed, whether at Supplier’s premises or elsewhere; and (b) all of Supplier’s facilities, books and records relating to this Order shall be subject to inspection by Buyer or its designee. If specific Buyer and/or Buyer’s customer tests, inspection and/or witness points are included in this Order, the goods shall not be shipped without an inspector’s release or a written waiver of test/inspection/witness with respect to each such point; however, Buyer shall not be permitted to unreasonably delay shipment; and Supplier shall notify Buyer in writing at least twenty (20) days prior to each of Supplier’s scheduled final and, if applicable, intermediate test/inspection/witness points. Supplier agrees to cooperate with such/audit inspection including, completing and returning questionnaires and making available its knowledgeable representatives. Buyer’s failure to inspect or test goods, materials or services or Buyer’s failure to reject or detect defects by inspection or testing shall not relieve Supplier from its warranty obligations or any of its other obligations or responsibilities under this Order. Supplier agrees to provide small business as well as minority and/or women owned business utilization and demographic data upon request.

  • Random Testing Notwithstanding any provisions of the Collective Agreement or any special agreements appended thereto, section 4.6 of the Canadian Model will not be applied by agreement. If applied to a worker dispatched by the Union, it will be applied or deemed to be applied unilaterally by the Employer. The Union retains the right to grieve the legality of any imposition of random testing in accordance with the Grievance Procedure set out in this Collective Agreement.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Commercial Operation Date Testing and Modifications Prior to the Commercial Operation Date, the Connecting Transmission Owner shall test the Connecting Transmission Owner’s Attachment Facilities (including required control technologies and protection systems) and System Upgrade Facilities and System Deliverability Upgrades and Developer shall test the Large Generating Facility and the Developer’s Attachment Facilities to ensure their safe and reliable operation. Similar testing may be required after initial operation. Developer and Connecting Transmission Owner shall each make any modifications to its facilities that are found to be necessary as a result of such testing. Developer shall bear the cost of all such testing and modifications. Developer shall generate test energy at the Large Generating Facility only if it has arranged for the injection of such test energy in accordance with NYISO procedures.